Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study - 06/08/11
, Tatsuya Ioka, MD b, Dirk J Richel, MD c, Jaafar Bennouna, MD d, Richard Létourneau, MD e, Takuji Okusaka, MD f, Akihiro Funakoshi, MD g, Junji Furuse, MD h, Young Suk Park, MD i, Shinichi Ohkawa, MD j, Gregory M Springett, MD k, Harpreet S Wasan, MB l, Peter C Trask, PhD m, Paul Bycott, PhD n, Alejandro D Ricart, MD n, Sinil Kim, MD n, Eric Van Cutsem, MD oSummary |
Background |
Axitinib is a potent, selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3. A randomised phase 2 trial of gemcitabine with or without axitinib in advanced pancreatic cancer suggested increased overall survival in axitinib-treated patients. On the basis of these results, we aimed to assess the effect of treatment with gemcitabine plus axitinib on overall survival in a phase 3 trial.
Methods |
In this double-blind, placebo-controlled, phase 3 study, eligible patients had metastatic or locally advanced pancreatic adenocarcinoma, no uncontrolled hypertension or venous thrombosis, and Eastern Cooperative Oncology Group performance status 0 or 1. Patients, stratified by disease extent (metastatic vs locally advanced), were randomly assigned (1:1) to receive gemcitabine 1000 mg/m2 intravenously on days 1, 8, and 15 every 28 days plus either axitinib or placebo. Axitinib or placebo were administered orally with food at a starting dose of 5 mg twice a day, which could be dose-titrated up to 10 mg twice daily if well tolerated. A centralised randomisation procedure was used to assign patients to each treatment group, with randomised permuted blocks within strata. Patients, investigators, and the trial sponsor were masked to treatment assignments. The primary endpoint was overall survival. All efficacy analyses were done in all patients assigned to treatment groups for whom data were available; safety and treatment administration and compliance assessments were based on treatment received. This study is registered at ClinicalTrials.gov, number NCT00471146.
Findings |
Between July 27, 2007, and Oct 31, 2008, 632 patients were enrolled and assigned to treatment groups (316 axitinib, 316 placebo). At an interim analysis in January, 2009, the independent data monitoring committee concluded that the futility boundary had been crossed. Median overall survival was 8·5 months (95% CI 6·9–9·5) for gemcitabine plus axitinib (n=314, data missing for two patients) and 8·3 months (6·9–10·3) for gemcitabine plus placebo (n=316; hazard ratio 1·014, 95% CI 0·786–1·309; one-sided p=0·5436). The most common grade 3 or higher adverse events for gemcitabine plus axitinib and gemcitabine plus placebo were hypertension (20 [7%] and 5 [2%] events, respectively), abdominal pain (20 [7%] and 17 [6%]), fatigue (27 [9%] and 21 [7%]), and anorexia (19 [6%] and 11 [4%]).
Interpretation |
The addition of axitinib to gemcitabine does not improve overall survival in advanced pancreatic cancer. These results add to increasing evidence that targeting of VEGF signalling is an ineffective strategy in this disease.
Funding |
Pfizer.
Le texte complet de cet article est disponible en PDF.Plan
Vol 12 - N° 3
P. 256-262 - mars 2011 Retour au numéro
Article précédent
- Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study
- Jack Cuzick, Gregory P Swanson, Gabrielle Fisher, Arthur R Brothman, Daniel M Berney, Julia E Reid, David Mesher, VO Speights, Elzbieta Stankiewicz, Christopher S Foster, Henrik Møller, Peter Scardino, Jorja D Warren, Jimmy Park, Adib Younus, Darl D Flake, Susanne Wagner, Alexander Gutin, Jerry S Lanchbury, Steven Stone, on behalf of the Transatlantic Prostate Group
- Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study
- Irene M Ghobrial, Edie Weller, Ravi Vij, Nikhil C Munshi, Ranjit Banwait, Meghan Bagshaw, Robert Schlossman, Renee Leduc, Stacey Chuma, Janet Kunsman, Jacob Laubach, Andrzej J Jakubowiak, Patricia Maiso, Aldo Roccaro, Philippe Armand, Akari Dollard, Diane Warren, Brianna Harris, Tiffany Poon, Amy Sam, Scott Rodig, Kenneth C Anderson, Paul G Richardson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?